Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
7 papers
Recent·Most cited
O. Aust, E. Blanc, M. Lüthen, V. Hollek, R. Astaburuaga-Garcia, B. Klinger, A. Trinks, D. Beule, B. Papke, D. Horst, N. Bluthgen, C. Sers, C. J. Der, M. Morkel
bioRxiv · Jul 1, 2024Cancer Biology
K. Kasack, P. Metzger, H. Koch, B. Klinger, A. Malek, O. Tchernitsa, A. Gross, W. Wruck, B. Györffy, B. Küster, C. Sers, M. Börries, R. Schäfer
This study identifies HMGA2 as a master regulator of mutant RAS-driven gene expression by analyzing time-resolved transcriptome and proteome changes in epithelial cells.
bioRxiv · Jun 4, 2024 · PreprintCancer Biology
T. Winogrodzki, A. Metwaly, A. Grodziecki, W. Liang, B. Klinger, K. Flisikowski, T. Flisikowska, K. Fischer, K. Steiger, D. Haller, A. Schnieke
This paper develops a genome-edited swine model of Crohn's disease that replicates key human disease features to enable translational research.
bioRxiv · Jul 8, 2022 · PreprintBioengineering
M. Dorel, B. Klinger, T. Mari, J. Toedling, E. Blanc, M. Nadler-Holly, M. Ziehm, A. Sieber, F. Hertwig, D. Beule, A. Eggert, J. H. Schulte, M. Selbach, N. Bluthgen
This study identifies feedback-mediated resistance to MEK inhibitors in neuroblastoma and shows that combining MEK with RAF or IGFR inhibitors can overcome resistance.
bioRxiv · Jun 14, 2021Cancer Biology
G. Niu, I. Hellmuth, T. Flisikowska, H. Pausch, B. Rieblinger, A. Carrapeiro, B. Schade, B. Boehm, E. Kappe, K. Fischer, B. Klinger, K. Steiger, D. Saur, J.-C. Bourdon, R. Burgkart, , K. Flisikowski
This study uses a porcine model to show that specific p53 isoforms and circular TP53 RNA drive tumorigenesis, particularly osteosarcoma, in pigs and likely have similar roles in humans.
bioRxiv · Sep 7, 2020 · PreprintCancer Biology
R. Brandt, T. Sell, M. Luethen, F. Uhlitz, B. Klinger, P. Riemer, C. Giesecke, S. Schulze, I. A. El-Shimy, D. Kunkel, B. Fauler, T. Mielke, N. Mages, B. G. Herrmann, C. Sers, , M. Morkel
The paper investigates how oncogenic KRAS and BRAF differentially activate ERK in colon cancer and intestinal epithelium, revealing cell type-specific effects and novel regulatory mechanisms.
bioRxiv · Feb 14, 2019Cell Biology
F. Eduati, V. Doldan-Martelli, B. Klinger, T. Cokelaer, A. Sieber, F. Kogera, M. Dorel, M. J. Garnett, N. Bluthgen, J. Saez-Rodriguez
The paper uses dynamic logic models of signaling pathways to predict drug sensitivity in colorectal cancer cell lines and identifies drug combinations to overcome resistance.
bioRxiv · Dec 16, 2016Cancer Biology